Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Burzynski Research Institute
WARNING LETTER
•Burzynski Research Institute•March 15, 2013

Burzynski Research Institute – FDA Warning Letter, Mar 15, 2013

Record Details

An FDA inspection at Burzynski Research Institute (BRI) from January to March 2013 revealed significant non-compliance with FDA regulations governing clinical investigations of Antineoplastons A10 and AS2-1, impacting human subject protection and data validity. Key violations included: 1) Failure to ensure proper monitoring and adherence to investigational plans/protocols (21 CFR 312.50, 312.56(a)), resulting in incorrect therapeutic response classifications due to non-compliance with criteria like corticosteroid use. 2) Failure to obtain informed consent per 21 CFR 312.60, 50.25(b)(3), 50.27(b)(1), specifically by omitting additional cost statements in consent forms and presenting billing agreements post-consent. FDA also noted BRI's SOPs incorrectly referenced 45 CFR part 46 and allowed IRB waiver of parental permission for children, which is not permitted under 21 CFR part 50, subpart D. 3) Failure to obtain sufficient financial information from 122 sub-investigators for disclosure statements (21 CFR 312.53(c)(4), Part 54). BRI's proposed corrective actions, including protocol amendments and revised consent wording, were deemed inadequate by the FDA for not fully addressing past non-compliance or committing to correct study records. BRI must address these deficiencies and establish compliant procedures, responding to FDA within 15 working days to prevent further regulatory action.

Company
Burzynski Research Institute
Inspection date
March 15, 2013
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Thomas N. Moreno
View Company Profile

ID · def8ec4c-7236-4a3e-997d-31a4d62c0ab3

Violation Codes10
21 CFR 312.5021 CFR 312.56(a)21 CFR 312.62(b)21 CFR 312.62(c)21 CFR 312.30(b)(1)(ii)21 CFR 312.30(2)(i)(a)21 CFR 312.6021 CFR 50.25(b)(3)21 CFR 50.27(b)(1)21 CFR 53(c)(4)

Full citation text and observation details available on the Dashboard.

Other documents for Burzynski Research Institute
  • 483 - 2006-06-06June 6, 2006

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Burzynski Research Institute
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.